Company profile
Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VK-2809 | phase2 | — | 3 | completed, withdrawn |
| VK-0214 | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04173065 | phase2 | completed | 2019-11-15 | 2023-05-15 | Viking Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH |
| NCT04973657 | phase1 | completed | 2021-06-22 | 2024-10-09 | Viking Therapeutics, Inc. | A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN |
| NCT02578095 | phase2 | completed | 2015-10-30 | 2017-11-15 | Viking Therapeutics, Inc. | Acute Hip Fracture Study in Patients 65 Years or Greater |
| NCT05203237 | phase1 | completed | 2021-12-14 | 2024-11-04 | Viking Therapeutics, Inc. | Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 |
| NCT02927184 | phase2 | completed | 2016-09-28 | 2019-03-26 | Viking Therapeutics, Inc. | Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease |
FDA applications (0)
No records yet.